Eli Lilly and Company (LLY) Position Held by State Farm Mutual Automobile Insurance Co.

State Farm Mutual Automobile Insurance Co. maintained its stake in shares of Eli Lilly and Company (NYSE:LLY) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,944,525 shares of the company’s stock at the end of the first quarter. Eli Lilly and comprises 2.4% of State Farm Mutual Automobile Insurance Co.’s portfolio, making the stock its 15th largest position. State Farm Mutual Automobile Insurance Co. owned about 1.89% of Eli Lilly and worth $1,677,535,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Sunbelt Securities Inc. boosted its stake in Eli Lilly and by 0.5% in the first quarter. Sunbelt Securities Inc. now owns 3,721 shares of the company’s stock valued at $313,000 after buying an additional 17 shares in the last quarter. Pillar Pacific Capital Management LLC boosted its stake in Eli Lilly and by 0.3% in the first quarter. Pillar Pacific Capital Management LLC now owns 7,077 shares of the company’s stock valued at $595,000 after buying an additional 20 shares in the last quarter. Rehmann Capital Advisory Group boosted its stake in Eli Lilly and by 0.9% in the first quarter. Rehmann Capital Advisory Group now owns 5,026 shares of the company’s stock valued at $423,000 after buying an additional 43 shares in the last quarter. Alpha Windward LLC boosted its stake in Eli Lilly and by 2.0% in the first quarter. Alpha Windward LLC now owns 2,251 shares of the company’s stock valued at $189,000 after buying an additional 44 shares in the last quarter. Finally, Joel Isaacson & Co. LLC boosted its stake in Eli Lilly and by 1.5% in the first quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock valued at $283,000 after buying an additional 50 shares in the last quarter. Institutional investors and hedge funds own 75.61% of the company’s stock.

Shares of Eli Lilly and Company (NYSE:LLY) opened at 82.07 on Tuesday. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $86.72. The stock has a 50 day moving average price of $82.99 and a 200 day moving average price of $81.53. The company has a market capitalization of $86.58 billion, a price-to-earnings ratio of 35.51 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.06. The business had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business’s revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.86 earnings per share. On average, equities analysts anticipate that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th will be given a $0.52 dividend. The ex-dividend date is Friday, August 11th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.53%. Eli Lilly and’s dividend payout ratio (DPR) is presently 90.04%.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Rincon Hill News and is owned by of Rincon Hill News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://rinconhillneighbors.org/2017/08/08/eli-lilly-and-company-lly-position-held-by-state-farm-mutual-automobile-insurance-co.html.

LLY has been the subject of several research analyst reports. UBS AG cut Eli Lilly and to a “hold” rating and set a $85.00 target price for the company. in a research report on Wednesday, July 26th. Piper Jaffray Companies reiterated a “buy” rating and set a $100.00 target price on shares of Eli Lilly and in a research report on Monday, April 17th. Argus cut Eli Lilly and from a “buy” rating to a “hold” rating and increased their target price for the stock from $64.18 to $81.00 in a research report on Thursday, April 27th. They noted that the move was a valuation call. Jefferies Group LLC reiterated a “buy” rating and set a $93.00 target price on shares of Eli Lilly and in a research report on Thursday, June 22nd. Finally, Sanford C. Bernstein reiterated an “outperform” rating and set a $88.00 target price on shares of Eli Lilly and in a research report on Sunday, May 21st. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $88.27.

In other news, VP Michael J. Harrington sold 22,833 shares of the company’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $79.97, for a total value of $1,825,955.01. Following the completion of the sale, the vice president now directly owns 62,056 shares in the company, valued at $4,962,618.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Melissa S. Barnes sold 1,900 shares of the company’s stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $80.78, for a total value of $153,482.00. Following the completion of the sale, the insider now owns 14,041 shares of the company’s stock, valued at $1,134,231.98. The disclosure for this sale can be found here. Insiders sold 669,733 shares of company stock valued at $55,845,287 over the last 90 days. Company insiders own 0.20% of the company’s stock.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eli Lilly and Company and related companies with our FREE daily email newsletter.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

seventeen + thirteen =